Global drugmaker AstraZeneca delivered better-than-anticipated profits for the second quarter of this year, the company announced Monday, while also standing by its financial projections heading into 2026.
Strong sales of the company’s cancer and heart disease therapies fueled the earnings beat. The results come at a time when AstraZeneca is working to reassure investors about its longer-term growth potential following a recent failure in one of its clinical trials.
